Global Bile Duct Cancer Drug Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Published Date: 2021-04-23
- Report ID: 104625
- Pages: 110
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Bile Duct Cancer Drug market in this environment.
In terms of revenue, this research report indicated that the global Bile Duct Cancer Drug market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Bile Duct Cancer Drug industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Ariad Pharmaceuticals, Inc. aims at producing XX K Units Bile Duct Cancer Drug in 2020, with XX % production to take place in global market, ArQule, Inc. accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Bile Duct Cancer Drug Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Bile Duct Cancer Drug Market
Ariad Pharmaceuticals, Inc.
ArQule, Inc.
Array BioPharma Inc.
Arrien Pharmaceuticals, LLC
Aslan Pharmaceuticals Pte. Ltd.
Bavarian Nordic A/S
Bayer AG
Blueprint Medicines Corporation
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
CellAct Pharma GmbH
Cellceutix Corporation
Cellular Biomedicine Group, Inc.
Concordia Healthcare Corp.
...
Major Type of Bile Duct Cancer Drug Covered in Prudent Markets report:
Cabozantinib S-malate
Elpamotide
Exatecan Mesylate
LY-2801653
NUC-1031
Others
Application Segments Covered in Prudent Markets Market
Hospital
Clinic
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Bile Duct Cancer Drug Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Cabozantinib S-malate -Product Introduction and Major Manufacturers
1.1.2 Elpamotide -Product Introduction and Major Manufacturers
1.1.3 Exatecan Mesylate -Product Introduction and Major Manufacturers
1.1.4 LY-2801653 -Product Introduction and Major Manufacturers
1.1.5 NUC-1031 -Product Introduction and Major Manufacturers
1.1.6 Others -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Bile Duct Cancer Drug Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Bile Duct Cancer Drug Market
3.1.1 Top Companies leading Bile Duct Cancer Drug Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Bile Duct Cancer Drug Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Bile Duct Cancer Drug Market
3.2.1 Top Companies leading Bile Duct Cancer Drug Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Bile Duct Cancer Drug Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Bile Duct Cancer Drug Market
3.3.1 Top Companies leading Bile Duct Cancer Drug Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Bile Duct Cancer Drug Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Bile Duct Cancer Drug Market
3.4.1 Top Companies leading Bile Duct Cancer Drug Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Bile Duct Cancer Drug Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Bile Duct Cancer Drug Market
3.5.1 Top Companies leading Bile Duct Cancer Drug Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Bile Duct Cancer Drug Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Bile Duct Cancer Drug Market
3.6.1 Top Companies leading Bile Duct Cancer Drug Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Bile Duct Cancer Drug Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Bile Duct Cancer Drug Market
3.7.1 Top Companies leading Bile Duct Cancer Drug Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Bile Duct Cancer Drug Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Bile Duct Cancer Drug Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Bile Duct Cancer Drug Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Bile Duct Cancer Drug Sales and Growth Rate (2021-2027)
5.2 Global Bile Duct Cancer Drug Sales Value and Growth Rate (2021-2027)
6 Bile Duct Cancer Drug Competitive Analysis
6.1 Ariad Pharmaceuticals, Inc.
6.1.1 Ariad Pharmaceuticals, Inc. Company Profiles
6.1.2 Ariad Pharmaceuticals, Inc. Product Introduction
6.1.3 Ariad Pharmaceuticals, Inc. Bile Duct Cancer Drug Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 ArQule, Inc.
6.2.1 ArQule, Inc. Company Profiles
6.2.2 ArQule, Inc. Product Introduction
6.2.3 ArQule, Inc. Bile Duct Cancer Drug Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Array BioPharma Inc.
6.3.1 Array BioPharma Inc. Company Profiles
6.3.2 Array BioPharma Inc. Product Introduction
6.3.3 Array BioPharma Inc. Bile Duct Cancer Drug Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 Arrien Pharmaceuticals, LLC
6.4.1 Arrien Pharmaceuticals, LLC Company Profiles
6.4.2 Arrien Pharmaceuticals, LLC Product Introduction
6.4.3 Arrien Pharmaceuticals, LLC Bile Duct Cancer Drug Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 Aslan Pharmaceuticals Pte. Ltd.
6.5.1 Aslan Pharmaceuticals Pte. Ltd. Company Profiles
6.5.2 Aslan Pharmaceuticals Pte. Ltd. Product Introduction
6.5.3 Aslan Pharmaceuticals Pte. Ltd. Bile Duct Cancer Drug Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Bavarian Nordic A/S
6.6.1 Bavarian Nordic A/S Company Profiles
6.6.2 Bavarian Nordic A/S Product Introduction
6.6.3 Bavarian Nordic A/S Bile Duct Cancer Drug Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Bayer AG
6.7.1 Bayer AG Company Profiles
6.7.2 Bayer AG Product Introduction
6.7.3 Bayer AG Bile Duct Cancer Drug Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Blueprint Medicines Corporation
6.8.1 Blueprint Medicines Corporation Company Profiles
6.8.2 Blueprint Medicines Corporation Product Introduction
6.8.3 Blueprint Medicines Corporation Bile Duct Cancer Drug Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 Boehringer Ingelheim GmbH
6.9.1 Boehringer Ingelheim GmbH Company Profiles
6.9.2 Boehringer Ingelheim GmbH Product Introduction
6.9.3 Boehringer Ingelheim GmbH Bile Duct Cancer Drug Production, Revenue (2016-2021)
6.9.4 SWOT Analysis
6.10 Boston Biomedical, Inc.
6.10.1 Boston Biomedical, Inc. Company Profiles
6.10.2 Boston Biomedical, Inc. Product Introduction
6.10.3 Boston Biomedical, Inc. Bile Duct Cancer Drug Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 Bristol-Myers Squibb Company
6.12 Celgene Corporation
6.13 CellAct Pharma GmbH
6.14 Cellceutix Corporation
6.15 Cellular Biomedicine Group, Inc.
6.16 Concordia Healthcare Corp.
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
